Literature DB >> 17229333

Use of single nucleotide polymorphism-based mapping arrays to detect copy number changes and loss of heterozygosity in multiple myeloma.

Brian A Walker1, Gareth J Morgan.   

Abstract

The genetics of multiple myeloma is a vastly studied field in which techniques such as classical cytogenetics, fluorescence in situ hybridization, and comparative genomic hybridization have been used. More recently, single nucleotide polymorphism (SNP)-based mapping arrays have become available that allow the identification of regions of gain or loss as small as 2.5 kb. In addition to the increased resolution of SNP-based arrays, the detection of loss of heterozygosity is also possible. This allows the identification of loss of heterozygosity regions that arise through monosomy and recombination, resulting in uniparental disomy, which cannot be detected by conventional genetic methods. In this review, we discuss the benefits of SNP-based arrays along with some of the drawbacks and how that data can be used in conjunction with expression data to identify genes with altered expression in regions of interest.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17229333     DOI: 10.3816/CLM.2006.n.057

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN: 1557-9190


  8 in total

1.  Genome-wide Mapping of Copy Number Variations Using SNP Arrays.

Authors:  Daniel Nowak; Wolf-Karsten Hofmann; H Phillip Koeffler
Journal:  Transfus Med Hemother       Date:  2009-07-10       Impact factor: 3.747

2.  Chediak-Higashi syndrome with early developmental delay resulting from paternal heterodisomy of chromosome 1.

Authors:  Irini Manoli; Gretchen Golas; Wendy Westbroek; Thierry Vilboux; Thomas C Markello; Wendy Introne; Dawn Maynard; Ben Pederson; Ekaterini Tsilou; Michael B Jordan; P Suzanne Hart; James G White; William A Gahl; Marjan Huizing
Journal:  Am J Med Genet A       Date:  2010-06       Impact factor: 2.802

Review 3.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

4.  Mapping of genetic abnormalities of primary tumours from metastatic CRC by high-resolution SNP arrays.

Authors:  José María Sayagués; Celia Fontanillo; María del Mar Abad; María González-González; María Eugenia Sarasquete; Maria del Carmen Chillon; Eva Garcia; Oscar Bengoechea; Emilio Fonseca; Marcos Gonzalez-Diaz; Javier De las Rivas; Luís Muñoz-Bellvis; Alberto Orfao
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

5.  Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.

Authors:  Nicholas J Dickens; Brian A Walker; Paola E Leone; David C Johnson; José L Brito; Athanasia Zeisig; Matthew W Jenner; Kevin D Boyd; David Gonzalez; Walter M Gregory; Fiona M Ross; Faith E Davies; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

6.  Association between genetic subgroups of pancreatic ductal adenocarcinoma defined by high density 500 K SNP-arrays and tumor histopathology.

Authors:  María Laura Gutiérrez; Luís Muñoz-Bellvis; María del Mar Abad; Oscar Bengoechea; María González-González; Alberto Orfao; José María Sayagués
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

7.  Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience.

Authors:  Jan Smetana; Jan Frohlich; Romana Zaoralova; Vladimira Vallova; Henrieta Greslikova; Renata Kupska; Pavel Nemec; Aneta Mikulasova; Martina Almasi; Ludek Pour; Zdenek Adam; Viera Sandecka; Lenka Zahradová; Roman Hajek; Petr Kuglik
Journal:  Biomed Res Int       Date:  2014-06-02       Impact factor: 3.411

8.  Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse.

Authors:  Jan Smetana; Jan Oppelt; Martin Štork; Luděk Pour; Petr Kuglík
Journal:  Mol Cytogenet       Date:  2018-01-18       Impact factor: 2.009

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.